>

Acoustic wave platform nebuliser for inhaled delivery of biologic therapies

Acoustic wave platform nebuliser for inhaled delivery of biologic therapies

The ability of biologic medicines to specifically target the underlying mechanisms of a wide range of diseases has driven substantial interest and investment in their development.

This momentum facilitated the rapid development and approval of the first messenger RNA (mRNA)-based vaccines during the COVID-19 pandemic, highlighting the potential of novel therapeutic platforms and encouraging a more optimistic outlook for future drug development.

For On Drug Delivery, our CSO Elijah Nazarzedeh discusses how Nebu~flow offers opportunities for drug delivery to, and through the lung.

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449